StemCell Therapy

The 83 rating InvestorsObserver gives to Cassava Sciences Inc (SAVA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 96 percent of stocks in the Biotechnology industry, SAVAs 83 overall rating means the stock scores better than 83 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cassava Sciences Inc (SAVA) stock has fallen -4.38% while the S&P 500 is higher by 1.42% as of 1:32 PM on Wednesday, Jan 20. SAVA is down -$0.57 from the previous closing price of $12.97 on volume of 1,890,973 shares. Over the past year the S&P 500 is higher by 16.02% while SAVA is higher by 57.16%. SAVA lost -$0.23 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Cassava Sciences Inc (SAVA) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Excerpt from:
Is Cassava Sciences Inc (SAVA) the Top Pick in the Biotechnology Industry? - InvestorsObserver

This entry was posted on January 25, 2021 at 12:53 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |